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Group-sequential strategies in clinical trials with multiple co-primary 
outcomes 
1 Introduction  
Traditionally in clinical trials, one outcome is selected as a primary endpoint and used as the 
basis for the trial design including sample size determination, interim monitoring, and final 
analyses. However, as the clinical benefit of an intervention is often characterized by a set of 
(potentially correlated) multiple outcomes, many recent clinical trials, especially in medical 
product development, have utilized more than one endpoint as co-primary (Often et al., 2007). 
“Co-primary” in this setting means that the trial is designed to evaluate if the intervention is 
superior to the control on all of the endpoints. If the superiority for any of endpoints is not 
achieved, then the intervention fails to demonstrate the superiority to control. Note that, in 
contrast, designing the trial to evaluate an effect on at least one of the endpoints is a different 
problem, referred to as “multiple primary endpoints” or “alternative primary endpoints” 
(Often et al., 2007). 
 In complex diseases, co-primary endpoints may be preferable as they offer the 
opportunity of characterizing intervention’s multidimensional effects. Regulators have issued 
guidelines recommending co-primary endpoints in several disease areas including 
Alzheimer’s disease, acute heart failure, diabetes mellitus, Duchenne and Becker muscular 
dystrophy, and irritable bowel syndrome. For example, the Committee for Medicinal Products 
for Human Use (CMHP) issued a guideline recommending the use of cognitive, functional, 
and global endpoints to evaluate symptomatic improvement of dementia associated with 
Alzheimer’s disease, indicating that primary endpoints should be stipulated reflecting the 
cognitive and functional disease aspects (CMHP, 2008). Offen et al. (2007) provides other 




 The resulting need for new approaches to the design and analysis of clinical trials with 
co-primary endpoints has been noted (Offen et al, 2007). Specifically controlling the Type I 
and Type II error rates when multiple ܭ co-primary endpoints are potentially correlated is 
non-trivial. In hypothesis testing for the ܭ  co-primary endpoints, the null hypothesis is 
rejected if and only if all of the null hypotheses associated with each of the ܭ endpoints are 
rejected at a significance level of ߙ. No adjustment is needed to control the Type I error rate if 
each endpoint is tested at the same prespecified significance level. The corresponding 
rejection region of the null hypothesis, defined as the intersection of ܭ regions associated 
with the ܭ co-primary endpoints is considerable restricted and thus the hypothesis testing is 
conservative, especially when the number of endpoints to be evaluated is large. On the other 
hand, when designing the trial with ܭ  co-primary endpoints, the overall power should be 
maintained to evaluate the joint effects on all of the ܭ endpoints. Since the Type II error rate 
increases as the number of endpoints increases, this requires the sample size adjustment and 
may often result in a sample size that is too large and impractical to conduct the clinical trial. 
In order to provide a more reasonable and practical sample size, methods for clinical trials 
with co-primary endpoints have been discussed in fixed sample size designs by many authors 
(Chuang-Stein et al., 2007; Hamasaki et al., 2013; Julious and Mclntyre, 2012; Kordzakhia et 
al., 2010; Offen et al, 2007; Senn and Bretz, 2007; Sozu et al., 2010, 2011, 2012, 2015; 
Sugimoto et al., 2012, 2013; Xiong et al., 2005). These methods commonly consider 
incorporating the correlations among the endpoints into the sample size calculation.  
 Hung and Wang (2009) discussed group-sequential strategies for clinical trials with 
multiple primary endpoints. These strategies provide the possibility of stopping a trial early 
when evidence is overwhelming, thus offering efficiency (i.e., potentially fewer patients than 
the fixed sample size designs). The methods also allow recalculation of the sample size based 
on the observed interim effects sizes. Recently Asakura et al. (2014, 2015) discuss two 
decision-making frameworks associated with hypothesis testing in clinical trials with two 
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continuous or binary endpoints as co-primary in a group-sequential setting. One framework is 
to reject the null hypothesis if and only if statistical significance is achieved for the two 
endpoints simultaneously (i.e., at the same interim timepoint of the trial). The other is a 
generalization of this, i.e., to reject the null hypothesis if superiority is demonstrated for the 
two endpoints at any interim timepoint (i.e., not necessarily simultaneously). The former 
framework is independently discussed by Chang et al. (2014) and evaluated in clinical trials 
with two co-primary endpoints. In the latter decision-making framework, Asakura et al. (2014, 
2015) assume that the same number of analyses with a common information level between the 
two endpoints, and the Type I error allocation to each interim look should be specified and 
determined in advance, using any alpha-spending function method. However, the latter 
decision-making framework can be further generalized to accommodate a varying number of 
analyses and equally or unequally spaced increments of information among the endpoints. 
 In the decision-making framework above, the maximum Type I error rate associated with 
the rejection region of the null hypothesis for co-primary endpoints is not inflated over the 
prespecified significance level. However, the rejection region of the null hypothesis is still 
restricted similarly as in the fixed sample size designs, because there is a requirement that the 
allocation of Type I error to each interim analysis for all of the endpoints, be prespecified. To 
relax the rejection region of the null hypothesis for co-primary endpoints, the decision-
making framework can be modified to allocate adaptively the Type I error to each interim 
look, using the methodology of hierarchical hypothesis testing with the adaptive Type I error 
allocation discussed in Tsong et al. (2004). However, Hung et al. (2007) cautions on the Type 
I error inflation in hierarchical hypothesis testing for detecting an effect on at least one 
endpoint in a group-sequential setting with multiple primary endpoints, and thus we need to 
investigate carefully how the Type I error rate behaves when using hierarchical hypothesis 





 The flexibilities and extensions mentioned above may improve the power and rejection 
region of the tests, providing efficiency. However the decision-making and operational issues 
associated with the trial will be more complex and challenging. The objective of the paper is 
to investigate the operating characteristics (overall power, Type I error, and sample size) of 
the three decision-making frameworks for group-sequential strategies in clinical trials with 
multiple co-primary endpoints. The first two frameworks are the extensions of works in 
Asakura et al (2014) and Cheng et al (2014) to multiple co-primary endpoints when 
appropriately planning for a potentially varying number of analyses and information levels 
with the prespecified and fixed Type I error allocation. The last framework is an extension of 
the work in Tsong (2004) to multiple co-primary endpoints with adaptive Type I error 
allocation. We discuss the fundamental features of the three frameworks. We will not discuss 
methods for adaptation based on effects observed at interim of a trial. For sample size 
recalculation based on the conditional power, please see Asakura et al. (2014) and Cheng et al 
(2014). Asakura et al (2014) have extensively discussed and evaluated the sample size 
recalculation based on the conditional power with Cui-Hung-Wang statistics (Cui et al., 1999). 
This paper is structured as follows: in Section 2 we outline the decision-making frameworks 
for group-sequential strategies in clinical trials with multiple co-primary endpoints and briefly 
describe the power and sample size calculations in Section 3. In Section 4, we evaluate the 
operating characteristics of the three decision-making frameworks including power, Type I 
error rate and sample sizes. We summarize the findings and discuss advantages and 
disadvantages of the three decision-making frameworks in Section 5.  
2 Group-sequential designs with co-primary endpoints 
2.1 Statistical Settings 
Consider a randomized, group-sequential clinical trial designed to compare test intervention 
(T) to control intervention (C), with ܭ continuous outcomes being evaluated as co-primary 
endpoints (ܭ ൒ 2). Now suppose that a maximum of ܮ analyses are planned. Let ݊௟ and ݎ݊௟ 
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be the cumulative number of participants on the test and the control intervention groups at the 
݈th analysis (݈ ൌ 1,… , ܮ), respectively, where the sampling ratio ሺݎ ൐ 0) is constant and not 
chosen arbitrarily during a clinical trial. Hence, up to ݊௅ and ݎ݊௅ participants are recruited 
and randomly assigned to either of the test and the control intervention groups, respectively. 
Then let responses to the test intervention denoted by ୘ܻ୩௜  and responses to the control 
intervention by େܻ௞௝  ሺ݇ ൌ 1,… , ܭ; 	݅ ൌ 1,… , ݎܰ; ݆ ൌ 1,… , ሺ1 െ ݎሻܰሻ . Assume that 
ሺ ୘ܻଵ௜, … , ୘ܻ௄௜ሻ  and ሺ େܻଵ௝, … , େܻ௄௝ሻ  are independently K-variate normally distributed as 
ሺ ୘ܻଵ௜, … , ୘ܻ௄௜ሻ~N௄ሺࣆ୘, ઱ሻ  and ൫ େܻଵ௝, … , େܻ௄௝൯~N௄ሺࣆେ, ઱ሻ , respectively, where ࣆ୘  and ࣆେ 
are mean vectors given by ࣆ୘ ൌ ሺߤ୘ଵ, … , ߤ୘௄ሻ୘ and ࣆେ ൌ ሺߤେଵ, … , ߤେ௄ሻ୘ respectively. For 
simplicity, ઱  is known covariance matrix given by ઱ ൌ ሼߩ௞௞ᇲߪ௞ߪ௞ᇲሽ  with varሾ ୘ܻ௞௜ሿ ൌ
varሾ େܻ௞௝ሿ ൌ ߪ௞ଶ  and 	corrሾ ୘ܻ௞௜, ܻ୘௞ᇲ௜ሿ ൌ corrሾ େܻ௞௝, ܻେ௞ᇲ௝ሿ ൌ ߩ௞௞ᇲሺ݇ ് ݇ᇱ; 1 ൏ ݇ ൏ ݇ᇱ ൑
ܭ;ܭ ൒ 2ሻ. 
 Let ߜ௞ denote the differences in the means for the test and the control intervention groups 
respectively, where ߜ௞ ൌ ߤ୘௞ െ ߤେ௞ሺ݇ ൌ 1,… , ܭሻ . Suppose that positive values of ߜ௞ 
represent the test intervention’s benefit. We are interested in testing the null hypothesis 
H଴: ߜ௞ ൑ 0  for at least one ݇  versus the alternative hypothesis Hଵ: ߜ௞ ൐ 0  for all ݇ . Let 
ሺܼଵ௟, … , ܼ௄௟ሻ be the statistics for testing the hypotheses at the ݈th analysis, given by ܼ௞௟ ൌ
ሺ തܻ୘௞௟ െ തܻେ௞௟ሻ ሺߪ௞ඥሺ1 ൅ ݎ௟ሻ ሺ݊௟ݎ௟ሻ⁄ ሻ⁄  where തܻ୘௞௟  and തܻେ௞௟  are the sample means given by 
തܻ୘௞௟ ൌ ݊௟ି ଵ ∑ ୘ܻ௞௜௡೗௜ୀଵ  and തܻେ௞௟ ൌ ሺݎ௟݊௟ሻିଵ ∑ େܻ௞௝௥೗௡೗௝ୀଵ . Thus, each ܼ௞௟ is normally distributed as 
Nሺඥݎ௟݊௟ ሺ1 ൅ ݎ௟⁄ ሻߜ௞ ߪ௞ൗ , 1ଶሻ under Hଵ. As the joint distribution of ሺܼଵ௟, … , ܼ௄௟ሻ is ܭ-variate 
normal with the correlation ߩ௞௞ᇲ  and the joint distribution of ሺܼ௞ଵ, … , ܼ௞௅ሻ is ܮ-variate normal 
with the correlation ඥ݊௟ ݊௟ᇲ⁄ ሺ1 ൑ ݈ ൑ ݈ᇱ ൑ ܮሻ , the joint distribution of 
ሺܼଵ௟, … , ܼ௄௟, … , ܼଵ௅, … , ܼ௄௅ሻ  is ܭ ൈ ܮ  multivariate normal with their correlation given by 




2.2 Decision-making framework A: Prespecified and fixed Type I error 
allocation 
When evaluating the joint effects on all ܭ endpoints within the context of group-sequential 
designs, a general decision-making framework associated with hypothesis testing is to reject 
H଴  if statistical significance of a test intervention relative to control is achieved for all 
endpoints at any interim timepoint until the final analysis (i.e., not necessarily 
simultaneously) (DF-A). If superiority is demonstrated on some but not all of the endpoints at 
the interim, then the trial will continue but subsequent hypothesis testing is repeatedly 
conducted only for the previously non-significant endpoint(s). Thus DF-A offers the 
opportunity of stopping measurement of an endpoint for which superiority has already been 
demonstrated. Stopping measurement may be desirable if the endpoint is very invasive or 
expensive (e.g., data from a liver biopsy or gastro-fiberscope, or data from expensive 
imaging). In addition, DF-A is a flexible strategy that allows the option of selecting different 
timings for interim looks among the endpoints. For example, when two endpoints are 
considered as co-primary and the number of analyses is four for one endpoint and three for 
the other endpoint, DF-A can allow for information times of 0.25, 0.50, 0.75 and 1.0 for one 
endpoint and 0.33, 0.67 and 1.0 for the other endpoint. However, the different timings for 
interim looks may create operational difficulty in conducting a clinical trial. For practical 
purposes, in Section 4, we will consider a situation where the timing of interim looks is the 
same among the endpoints, e.g., 0.25, 0.50, 0.75 and 1.0 for one endpoint and 0.50, 0.75 and 
1.0 for the other endpoint. 
 Here suppose that ܮ௞  analyses are planned for each endpoint and a total number of 
analyses ܮ  is the sum of the number of analyses over all of the endpoints excluding the 
duplications of the same information time ݊௟ೖ ݊௅⁄ ൌ ݊௟ೖᇲ ݊௅⁄ . The stopping rule for DF-A is 
formally given as follows: 
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Until the ݈th analysis (݈ ൌ 1,… , ܮ െ 1), 
 If ܼ௞௟ೖ ൐ ܿ௞௟ೖ for all ܭ endpoints for some 1 ൑ ݈௞ ൑ ݈, then reject H଴ and stop the trial, 
 otherwise, continue to the ሺ݈ ൅ 1ሻth analysis, 
at the ܮth analysis, 
 if ܼ௞௅ೖ ൐ ܿ௞௅ೖ for non-significant endpoint(s) until the ሺܮ െ 1ሻth analysis, then reject 
H଴, 
 otherwise, do not reject H଴, 
where ܼ௞௟ೖ  are the test statistics at the ݈௞th analysis for the ݇th endpoint, ܿ௞௟ೖ are the critical 
values at the ݈௞th analysis for the ݇th endpoint. Note that ܿ௞௟ೖ are prespecified and determined 
separately, using any group-sequential methods such as the Lan-DeMets (LD) alpha-spending 
method (Lan and DeMets, 1984) to control an overall Type I error rate of ߙ, as if they were a 
single primary endpoint, ignoring the other co-primary endpoint(s). Therefore, the overall 
power (or conjunctive power) corresponding to DF-A is 
1 െ ߚ ൌ Pr ቂቄ⋃ ൛ܼଵ௟భ ൐ ܿଵ௟భൟ௅భ௟భୀଵ ቅ ∩ ⋯∩ ቄ⋃ ൛ܼ௄௟಼ ൐ ܿ௄௟಼ൟ௅಼௟಼ୀଵ ቅ|Hଵቃ. (1) 
 DF-A is flexible, but stopping measurement may also introduce operational challenges 
into the trial. To avoid the operational difficulties, we may opt for a restriction regarding 
when 0H  is rejected and the trial is stopped. The simplified version of DF-A is to reject 0H  if 
superiority is demonstrated on all of the endpoints at an interim simultaneously. If any of the 
endpoints is not significant, then then the trial continues until the joint significance for all 
endpoints is established simultaneously (DF-A’). The stopping rule for DF-A’ is formally 
given as follows: 
At the ݈th analysis (݈ ൌ 1,… , ܮ), 
 If ܼ௞௟ ൐ ܿ௞௟ for all ܭ endpoints simultaneously, then reject H଴ and stop the trial, 




 at the ܮth analysis, 
 if ܼ௞௅ ൐ ܿ௞௅ for all ܭ endpoints simultaneously, then reject H଴, 
 otherwise, do not reject H଴. 
Therefore, the overall power corresponding to DF-A’ is a special case of DF-A, 
1 െ ߚ ൌ Prൣ⋃ ൛ሼܼଵ௟ ൐ ܿଵ௟ሽ ∩ ⋯∩ ሼܼ௄௟ ൐ ܿ௄௟ሽൟ௅௟ୀଵ |Hଵ൧. (2) 
DF-A’ is simpler but less powerful than DF-A. This will be illustrated in Section 4. 
2.3 Decision-making framework B: Hierarchical hypothesis testing with 
adaptive Type I error allocation 
For the methods discussed in the previous section, the rejection region of the null hypothesis 
is still restricted, as with the fixed sample size designs, because the allocation of Type I error 
to each interim analysis for all endpoints should be prespecified using an alpha-spending 
method. To overcome the issue, the decision-making framework can be modified to allocate 
adaptively the Type I error to each interim look, using the methodology of hierarchical 
hypothesis testing with adaptive Type I error allocation. This idea is discussed by Tsong et al. 
(2004) in group-sequential three-arm clinical trials when assessing the equivalence and 
efficacy of a generic product, where the co-primary objectives of the study are to assess 
whether the generic and reference product are effective relative to placebo and whether the 
generic is equivalent to the reference product with a prespecified equivalence margin. Their 
method evaluates equivalence only after both null hypotheses of efficacy are rejected and then 
to specify the Type I error allocation before the equivalence evaluation is performed.  
 When extending the hierarchical hypothesis testing with adaptive Type I error allocation 
to clinical trials with multiple endpoints as co-primary, the order of the hypothesis testing for 
each endpoint is determined even when the endpoints are equally important and the Type I 
error allocation for the first-tested endpoint is prespecified, using an alpha spending method, 
where a maximum of planned analyses for the first-tested endpoint is ܮଵ. If superiority is 
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established for the first-tested endpoint at ݈ଵ th analysis with information time ܫ௟ଵ ൌ
݊௟ଵ ݊௅⁄ (0 ൏ ܫ௟ଵ ൑ 1 ), then the Type I error allocation for the second-tested endpoint is 
specified before the hypothesis testing for the second-tested endpoint is performed, where a 
maximum of planned analyses for the second-tested endpoint is ܮଶ. If superiority has been 
established for the second-tested endpoint at ݈ଶth analysis with information time ܫ௟ଶ ൌ ݊௟ଶ ݊௅⁄  
(ܫ௟ଵ ൑ ܫ௟ଶ ൑ 1), then the Type I error allocation for the third-tested endpoint is specified 
before the hypothesis testing for the third-tested endpoint is performed. These steps are 
repeated for ܭth-tested endpoint until H଴ is rejected. The stopping rule for DF-B is formally 
given as follows: 
For ݇th-tested endpoint (1 ൑ ݇ ൑ ܭ), at the ݈௞th analysis (݈௞ ൌ 1,… , ܮ௞ െ 1), 
 If ܼ௞௟ೖ ൐ ܿ௞௟ೖ, then specify the Type I error allocation for ሺ݇ ൅ 1ሻth-tested endpoint, 
using any alpha-spending method 
 otherwise, continue to the ሺ݈௞ ൅ 1ሻth analysis, 
 at the ܮ௞th analysis,  
 if ܼ௞௅ೖ ൐ ܿ௞௅ೖ, then specify the Type I error allocation for ሺ݇ ൅ 1ሻth-tested endpoint, 
using alpha-spending methods 
 otherwise, do not reject H଴. 
For ܭth-tested endpoint at the ݈௄th analysis (݈௄ ൌ 1,… , ܮ௄ െ 1), 
 if ܼ௄௟಼ ൐ ܿ௄௟಼, then reject H଴ and stop the trial, 
 otherwise, continue to the (݈௄ ൅ 1)th analysis, 
 at the ܮ௄th analysis,  
 if ܼ௄௅಼ ൐ ܿ௄௅಼, then reject H଴ and stop the trial, 
 otherwise, do not reject H଴. 
For example, consider a clinical trial with two co-primary endpoints, where the maximum 




information and the O’Brien-Fleming-type boundary is used to reject the null hypothesis for 
the first-tested endpoint with the significance level of ߙ ൌ2.5% for a one-sided test. The 
second-tested endpoint is evaluated only after the null hypothesis for the first-tested endpoint 
is rejected. The second endpoint is tested at the remaining planned analyses for the first-tested 
endpoint, and the O’Brien-Fleming-type boundary (O’Brien and Fleming, 1979) is used to 
reject the null hypothesis for the second-tested endpoint with the significance level of 
ߙ ൌ2.5% for a one-sided test, as shown in Table 1. If the first-tested endpoint is statistically 
significant at the 4th look, then the second-tested endpoint is tested twice with the boundary 
of 2.2504 at 4th analysis and 2.0249 at the final analysis. 
 The overall power for DF-B is 
1 െ ߚ ൌ Pr ቈ⋃ ቊ൛ܼଵ௟భ ൐ ܿଵ௟భൟ ∩ ൜⋯∩ ቄ⋃ ൛ܼ௄௟಼ ൐ ܿ௄௟಼ൟ௅಼௟಼ୀଵ ቅൠቋ௅భ௟భୀଵ |Hଵ቉. (3) 
For the sample size calculation, the number of interim analyses and the information time for 
all of the endpoints should be prespecified. As mentioned in Section 1, Hung et al. (2007) 
discuss the behavior of the Type I error rate when hierarchical hypothesis testing is used for 
detecting an effect on at least one endpoint in a group-sequential setting and caution that the 
conventional hierarchical testing strategy may violate the closed testing principle and thus the 
overall Type I error rate may not be controlled in the strong sense. They show that, when 
considering the two endpoints as primary and testing the two hypotheses for the two 
endpoints with the hierarchical order, the Type I error rate for the second endpoint is inflated 
over the prespecified significance level, depending on the effect size for the first endpoint and 
correlation between the endpoint. Thus DF-B may not control the Type I error rate adequately. 
This will be further evaluated in Section 4 and the Appendix. 
3. Calculation for power and sample sizes 
The powers (1), (2) and (3) defined in the previous sections can be evaluated using the 
numerical integration method in Genz (1992) or other methods. The power calculation 
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requires considerable computing time and memory especially with a large number of 
endpoints or number of analyses. The accuracy of the computation should be carefully 
controlled as it is sensitive to the number of endpoints and the number of analyses.  
 We describe two sample size concepts, i.e., the maximum sample size (MSS) and the 
average sample number (ASN) (i.e., expected sample size) based on the power (1), (2) or (3). 
The MSS is the sample size required for the final analysis to achieve the desired power 1 െ ߚ. 
The MSS is given by the smallest integer not less than ݊௅ satisfying the power for a group-
sequential strategy at the prespecified ߜ௞  and ߩ௞௞ᇲ , with Fisher’s information time for the 
interim analyses, ݊௟ ݊௅⁄  (݈ ൌ 1,… , ܮ). To identify the value of ݊௅, an easy strategy is a grid 
search to gradually increase (or disease) ݊௅ until the power under ݊௅ exceeds (or falls below) 
the desired power. As seen in Appendix 1, the grid search often requires considerable 
computing time, especially with a larger number of endpoints, a larger number of analyses, or 
a small effect size. To reduce the computing time, the Newton–Raphson algorithm in 
Sugimoto et al. (2012) or the basic linear interpolation algorithm in Hamasaki et al. (2013) 
may be utilized. In this paper, we use of the basic linear interpolation algorithm to reduce the 
computing time.  
 The ASN is the expected sample size under hypothetical reference values and provides 
information regarding the number of participants anticipated in a group-sequential design in 
order to reach a decision point, and the ASN per intervention group is given by 
ASN ൌ ∑ ݊௟ ௟ܲሺߜଵ, … , ߜ௄ሻ௅ିଵ௟ୀଵ ൅ ݊௅൫1 െ ∑ ௟ܲሺߜଵ, … , ߜ௄ሻ௅ିଵ௟ୀଵ ൯, 
where ௟ܲሺߜଵ, … , ߜ௄ሻ is stopping probability (or exit probability) as defined the likelihood of 
crossing the critical boundaries at the ݈ th interim look assuming the true values of the 
intervention’s effect are ሺߜଵ, … , ߜ௄ሻ.  
 Both MSS and ASN depend on the design parameters including differences in means, the 




spending method (e.g., O’Brien-Fleming-type boundary, Pocock-type boundary (Pocock, 
1977)), the number of analyses, and equally or unequally spaced increments of information. 
 Our experience suggests that, as shown in Appendix, when considering more than two 
endpoints as co-primary in a group-sequential setting with more than five analyses, 
calculating the multivariate normal integrals often requires considerable computing time. A 
Monte-Carlo simulation-based method provides an alternative but the number of replications 
for simulations should be carefully chosen to control simulation error in calculating the 
empirical power. 
4. Operating characteristics of the decision-making frameworks in group-
sequential strategies 
In this section, we investigate the operating characteristics of the decision-making 
frameworks for the group-sequential strategies described in the previous section including the 
overall Type I error rate, overall power and ASN under a given sample size, of one-sided test. 
and For illustration, we consider a simple situation, i.e., a randomized clinical trial designed 
to compare a test intervention to a control intervention with two outcomes being evaluated as 
co-primary endpoints. We evaluate the operating characteristics of the decision-making 
frameworks for group-sequential strategies shown in Tables 2 and 3. They include clinical 
trials with a maximum number of analyses of 2 or 5, and equally spaced increments of 
information for one endpoint, but unequally spaced increments for other endpoint, with a 
common variance ߪଵ ൌ ߪଶ ൌ1.0. One-sided statistical testing is conducted at the significance 
level of α ൌ2.5%. A range of correlation between the two outcomes considered in the 
evaluation is , ߩଵଶ ൒ 0 since the correlation among the endpoints are usually nonnagetive as 
discussed in Often et al (2007). The overall power and Type I error rate is evaluated using the 
numerical integration method in Genz (1992). However, the accuracy of the computation for 
the overall power and Type I error rate may depend on the number of analyses. Therefore, 
 13 
 
Monte-Carlo simulation was also performed to confirm the result from the numerical 
integration method. A total of 100,000 replications and 1,000,000 replications are selected for 
the assessments of power and Type I error rate respectively. The number of replications was 
determined based on the precision, where a sample size of 1,000,000 provides a two-sided 
95% confidence interval with a width equal to 0.001 when the proportion is 0.025, and 
100,000 replications provides a two-sided 95% confidence interval with a width equal to 
0.005 when the proportion is 0.80. The results presented in this manuscript were by the 
numerical integration methods, but the Monte-Carlo simulation confirmed these results.  
4.1 Behaviors of the overall Type I error rate 
Figures 1 (ܮ ൌ2) and 2 (ܮ ൌ5) illustrate the behaviors of the Type I error rate with correlation 
under a given sample size per group (equally-sized groups: ݎ ൌ1) in the decision-making 
frameworks for group-sequential strategies with two co-primary endpoints as shown in Tables 
2 and 3. The effect size ሺߜଵ, ߜଶሻ selected were (0.2, 0.2), (0.3, 0.2) and (0.2, 0.3) and the given 
sample sizes per group are calculated to detect the joint effect of ሺߜଵ, ߜଶሻ with the power of 
80% at the significance level of 2.5% for a one-sided test in a fixed sample size design; they 
are 516 for ሺߜଵ, ߜଶሻ ൌ (0.2, 0.2), and 402 for ሺߜଵ, ߜଶሻ ൌ (0.3, 0.2) or ሺߜଵ, ߜଶሻ ൌ (0.2, 0.3), 
which The critical values are determined based on the O’Brien–Fleming-type boundary (OF) 
(O’Brien and Fleming, 1979), Pocock-type boundary (PC) (Pocock, 1979) or their 
combinations, using with the LD alpha-spending method. Then four stopping boundary 
combinations are considered: (i) the OF for both endpoints (OF-OF), (ii) the OF for ߜଵ and 
the PC for ߜଶ (OF-PC), (iii) the PC for ߜଵ and the OF for ߜଶ (PC-OF), and (iv) the PC for both 
endpoints (PC-PC). The overall Type I error rate is evaluated under three pairs of the mean 
differences ሺߜଵ, ߜଶሻ ൌ (0.0, 0.0), (0.0, 0.2) and (0.2, 0.0). 
 In the case of ܮ ൌ2, in all stopping boundary combinations and effect size combinations, 




among the strategies. For Strategies #2 (DF-A’), #3 (DF-A) and #4 (DF-A), the Type I error 
rate increases as the correlation goes toward one, but does not exceed the targeted 
significance level of 2.5% in all of the stopping boundary combinations and effect size 
combinations. Strategy #4 provides a larger Type I error rate than Strategy #3, illustrating that 
delaying the analysis for Endpoint 2 relaxes the Type I error rate. 
 For Strategy #1 (DF-B), similarly as seen in Strategies #2, #3 and #4, the Type I error 
rate increases as the correlation goes toward one, but does not exceed the targeted 
significance level of 2.5%, in all of the stopping boundary combinations and effect size 
combinations except for ሺߜଵ, ߜଶሻ ൌ (0.2, 0.0). However, in all of the stopping boundary 
combinations with effect size combination ሺߜଵ, ߜଶሻ ൌ (0.2, 0.0), it does exceed the targeted 
significance level of 2.5%, especially in the stopping boundary combination of PC-OF or PC-
PC. 
 In the case of	ܮ ൌ 5, the behaviors of the Type I error rate are similar to that seen with 
ܮ ൌ2. Strategy # 2 (DF-A’) is the most conservative as it provides the smallest Type I error 
rate among the strategies. For Strategies #3 to #6, the Type I error rate increases as the 
correlation goes toward one, but does not exceed the targeted significance level of 2.5% in all 
of the stopping boundary and effect size combinations. However, for Strategy #1, in all of the 
stopping boundary combinations with effect size combination ሺߜଵ, ߜଶሻ ൌ(0.2, 0.0), it does 
exceed the targeted significance level of 2.5%.  
 The two decision-making frameworks with the prefixed Type I error allocation 
adequately controls the Type I error rate but the decision-making framework with the 
adaptive Type I error allocation may not control the Type I error rate. The Type I error rate is 
inflated depending on the correlation, effect sizes, and stopping boundary. Details are 
provided in the Appendix. Further investigation is needed to understand  how the Type I error 
rate for the DF-B behaves in the original context of Tsong et al. (2004), i.e., group-sequential 
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three-arm clinical trials with a single primary endpoint when assessing the equivalence and 
efficacy of a generic product. 
4.2 Behaviors of the overall power and ASN 
Figures 3 (ܮ ൌ2) and 4 (ܮ ൌ5) illustrate the behaviors of overall power, and Figures 5 (ܮ ൌ2) 
and 6 (ܮ ൌ5) illustrate the behaviors of ASN with correlation under a given sample size per 
group in the decision-making frameworks for group-sequential strategies with two co-primary 
endpoints as shown in Tables 2 and 3. The parameter configuration and setting regarding 
sample sizes and stopping boundaries are the same as other figures. 
 In the case of ܮ ൌ2, when effect sizes are equal, the powers of all of the decision-making 
frameworks increase as the correlation goes toward one, but they do not vary with correlation 
with unequal effect sizes in all the stopping boundary combinations and effect size 
combinations. The highest power is commonly given by Strategies #4 (DF-A) or/and #1 (DF-
B) and the lowest power is commonly given by Strategy #2 (DF-A’). On the other hand, when 
effect sizes are equal, the ASNs for all of the decision-making frameworks decrease as the 
correlation goes toward one, but they do not vary with correlation with unequal effect sizes in 
all the stopping boundary combinations and effect size combinations. The smallest ASN is 
given by Strategies #2 (DF-B) and #3 (DF-A) and the largest ASN is given by Strategies #1 
(DF-A’) and #4 (DF-A).  
 Similar behaviors for the power and ASN are observed in case of ܮ ൌ5. The powers for 
all of the decision-making frameworks increase as correlation goes toward one, but they do 
not vary with the correlation with unequal effect sizes in all the stopping boundary 
combinations and effect size combinations. The highest power is commonly given by 
Strategies #6 (DF-A) or/and #1 (DF-B) and the lowest power is commonly given by Strategy 
#2 (DF-A’). On the other hand, when effect sizes are equal, the ASNs for all decision-making 




with unequal effect sizes in all the stopping boundary combinations and effect size 
combinations. The smallest ASN is given by Strategy #2 (DF-B) and the largest ASN is given 
by Strategy #6 (DF-A). In summary, delaying the analysis for one of the endpoints increases 
the power but increases ASN. 
5. Summary and discussion 
The determination of sample size and the evaluation of power are fundamental and critical 
elements in the design of a clinical trial. If a sample size is too small then important effects 
may not be detected, while a sample size that is too large is wasteful of resources and 
unethically puts more participants at risk than necessary. Recently many clinical trials have 
been designed with more than one endpoint considered as primary. When utilizing multiple 
endpoints in clinical trials, we must distinguish between the two inferential goals of clinical 
trials based on multiple endpoints, i.e., a decision must be made as to whether it is desirable to 
evaluate the joint effects on all endpoints or at least one of the endpoints. The former is 
referred as to “multiple co-primary endpoints” and the latter as to “multiple primary endpoints” 
(Offen et al., 2007). In this paper, we discuss methods for multiple co-primary endpoints. Co-
primary endpoints offer an attractive design feature as they capture a more complete 
characterization of the effect of an intervention. However co-primary endpoints create 
challenges in the evaluation of power and the calculation of sample size during trial design as 
the power is decreased and the sample size is increased with the larger number of endpoints. 
Currently utilized methods often result in large and impractical sample sizes. 
 In this paper, as an extension of the work in Asakura et al. (2014, 2015), we consider 
three decision-making frameworks for group-sequential strategies with multiple co-primary 
endpoints when appropriately planning for a varying number of analyses for each endpoint 
and equally or unequally spaced increments of information when the trial is designed to 
evaluate if a new intervention is superior to a control on all of the endpoints. We also consider 
the use of hierarchical hypothesis testing methodology with the adaptive Type I error 
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allocation, which was discussed by Tsong et al. (2004). Then we investigate the operating 
characteristics of group-sequential strategies for clinical trials with multiple co-primary 
endpoints. Based on the investigations, our findings are summarized in Table 4. 
 The decision-making framework using hierarchical hypothesis testing with adaptive 
Type I error allocation (DF-B) has the attractive features of providing higher power and 
smaller sample sizes compared with the decision-making frameworks with prespecified and 
fixed Type I error allocation (DF-A or DF-A’). However, the Type I error rate is inflated and 
depends on the correlation, effect sizes, and the stopping boundary. As seen in clinical trials 
with two co-primary endpoints, the correlation between the endpoints and the effect size of 
the first-tested endpoint are the nuisance parameters that determine the stopping boundary and 
then the level of the Type I error. In practice, use of DF-B should be carefully considered. In a 
similar but not identical setting, i.e., at least one endpoint with one interim analysis, and one 
primary and one secondary endpoints, the behavior of the Type I error for hierarchical 
hypothesis testing has been well-studied (Glimm et al, 2010; Hung et al, 2007; Tamhane et al, 
2010). By the analogy between these studies and the investigation given in Appendix 2, one 
simple solution is to test the hypothesis for the second-tested endpoint only once although 
further investigation will be required to evaluate more general situations with more than two 
analyses. 
 The decision-making framework with prespecified and fixed Type I error allocation (DF-
A or DF-A’) can adequately control the Type I error rate. They are less powerful than DF-B, 
but differences in power and required sample sizes are very modest. Especially, when the 
O’Brien-Fleming-type boundary is selected for both endpoints, there is little difference in 
power, maximum sample size, and average sample number. DF-A provides the flexibility of 
selecting differently spaced information levels and different numbers of analyses among the 
endpoints. In some clinical trials, information for the endpoints may not accrue at the same 




oncology trials and require different information times. DF-A is useful when designing 
clinical trials with such endpoints. Strategic selection regarding the number of analyses with 
equally or unequally spaced information level among the endpoints may improve the power 
and reduce the sample sizes. However, when selecting a different number of analyses among 
the endpoints, early interim evaluations should be carefully evaluated as they can provide 
higher power but larger average sample numbers. DF-A also offer the option of stopping 
measurement of an endpoint for which superiority has been demonstrated. This may be 
desirable if the endpoint is very invasive or expensive. However, these complexities may raise 
operational challenges. Stopping measurement after interim analysis can raise a major 
concern about study integrity and can affect the validity of the statistical conclusions reached 
for a clinical trial. In practice, we should carefully consider how to minimize this risk. 
 When constructing efficient group-sequential strategies in clinical trials with multiple co-
primary endpoints, there are two practical questions. The first question is the choice of the 
stopping boundary based on an alpha-spending function for each endpoint. If the trial was 
designed to detect effects on at least one endpoint with a prespecified ordering of endpoints, 
then the selection of different boundaries for each endpoint (i.e., the O’Brien-Fleming-type 
for the primary endpoint and the Pocock-type boundary for the secondary endpoint) can 
provide a higher power than using the same boundary for both endpoints (Glimm et al., 2010; 
Tamhane et al., 2010). However, as shown in Section 4, the selection of a different boundary 
has a minimal effect on the overall power and average sample number. In all of the three 
decision-making frameworks, regardless of equal or unequal effect sizes among the endpoints, 
the largest power is obtained from the O’Brian-Fleming-type boundary for all of the 
endpoints, and the lowest is the Pocock-type boundary for all of the endpoints. Regarding the 
average sample number, the smallest is provided by the Pocock-type boundary for all of the 
endpoints, the largest is provided by the O’Brian-Fleming-type boundary. One possible 
scenario for selecting a different boundary is when one endpoint is invasive and stopping to 
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measurement of the endpoint is desirable as soon as possible, i.e., once the superiority for the 
endpoint has been demonstrated. Table 5 illustrates the expected number of observations per 
intervention group for each endpoint based on the decision-making frameworks DF-A under a 
given maximum sample size in clinical trials with two co-primary endpoints, EP1 and EP2. 
The expected number of observations for each endpoint is calculated under the hypothetical 
reference values and provides information on the number of observations anticipated in a 
group-sequential design in order to reach a decision point for each endpoint. The maximum 
sample size per intervention group (equally-sized group) is calculated to detect the joint effect 
for two endpoints ሺߜଵ, ߜଶሻ (ߪଵ ൌ ߪଶ ൌ 1ሻ with the overall power of 80% at the significance 
level of 2.5% for a one-sided test, where one interim and one final analysis are to be 
performed, the critical values are determined by the O’Brian-Fleming-type boundary, the 
Pocock-type boundary and their combinations, using the Lan-DeMets alpha-spending method 
with equally-spaced increments of information, and ሺߜଵ, ߜଶሻ ൌ(0.2, 0.2), (0.2, 0.3) and (0.3, 
0.2) are selected. If EP1 is an invasive endpoint, then the combination of the Pocock-type 
boundary for EP1 and the O’Brian-Fleming-type boundary for EP2, provides the smallest 
expected number of observations for EP1 in all of the effect size combinations.  
 Another practical question is the selection of the correlations in the power evaluation and 
sample size calculation, i.e., whether the observed correlation from external or pilot data 
should be utilized. One conservative approach is to assume that the correlations are zero even 
if non-zero correlations are expected. Group-sequential designs discussed in this paper offer 
the possibility of reducing the sample size compared to fixed sample size designs even if zero 
correlation is assumed at the design stage. For example, when considering a clinical trial with 
two co-primary endpoints, 490 participants per intervention group is required to detect a joint 
effect of equal effect sizes ሺߜଵ, ߜଶሻ ൌ (0.2, 0.2) with the overall power of 80% at the 
significance level of 2.5% for a one-sided test in a fixed sample size design, if the correlation 




conservatively assuming zero correlation between the two endpoints, the maximum sample 
sizes are 518, 523, 528 and 530 corresponding to the number of analyses ܮ ൌ2, 3, 4 and 5, 
using the O’Brian-Fleming-type boundary based on the Lan-DeMets alpha-spending function 
for both endpoints with equally-spaced increments of information. Under these maximum 
sample sizes, the average sample numbers are 488, 455, 442 and 434. The average sample 
numbers are approximately equal or smaller than the fixed sample designs, depending on the 
number of analyses. Our experience suggests that when standardized effect sizes are unequal 
among the endpoints, then the power is not increased with higher correlations. With unequal 
standardized effect sizes, incorporating the correlation into the sample size calculation at the 
planning stage may have less of an advantage because the sample size is determined by the 
smaller effect size. 
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Appendix 1: Computation time for calculating sample sizes 
The program for calculating the power and sample size is coded in FORTAN 77/90, including 
the subroutine for computing the multivariate normal distribution function values, MVNDST 
developed by Professor Alan Genz of Washington State University (the subroutine MVNDST 
is available on at his website http://www.math.wsu.edu/faculty/genz/software/fort77/). The 
speed of execution heavily depends upon the speed of MVNDST, and is a function of the 
number of endpoints, the number of analyses, and the required accuracy for computation. In 
our study, computing the multivariate normal distribution function values using the subroutine 
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MVNDST began with a maximum number of function values (MAXPTS) of 5000, an 
absolute error tolerance (ABSEPS) of 0.00001, and a relative error tolerance (RELEPS) of 
zero. If the estimated absolute error (ERROR) is larger than required tolerance (ABSEPS), i.e., 
ERROR > ABSEPS, then MAXPTS is increased by 1000 to decrease the estimated absolute 
error.  
 To illustrate the computational cost, Table A1 shows the CPU time (in seconds) taken for 
calculating the sample size on a DELL Precision T7300 (Intel® Xeon® CPU E5-
2630/2.60GHz/RAM 8.00GB/32bit operating system) for DF-A with the number of endpoints 
(݇) and the number of analyses (ܮ), where ݇ ൌ2 and 3; ܮ ൌ2, 3, 4, 5, 8 and 10; a common 
effect size ߜ ൌ ߜ௞ ൌ 0.2, and common correlation ߩ ൌ ߩ௞௞ᇲ ൌ 0.5. The sample size is 
calculated to detect a joint effect on all endpoints with the power of 80% at the significance 
level of 2.5% for a one-sided test, where the O’Brian-Fleming-type boundary is commonly 
selected for all of the endpoints, with equally spaced increments of information. We here 
consider the two methods for calculating sample sizes; one is a grid search to decrease ݊ 
gradually (decrease by one) until the power under ݊ falls below the desired overall power of 
1 െ ߚ (Method 1), and the other is an iterative procedure based on linear interpolation to 
identify ݊ discussed in Hamasaki et al (2013) (Method 2). When the effect sizes are similar 
among the endpoints and the same stopping boundary is selected for all the endpoints, then 
the required sample size sample size lies between the two values ݊୫୧୬ and ݊୫ୟ୶, where ݊୫୧୬ 
and ݊୫ୟ୶  are the sample sizes calculated to have the power of 1 െ ߚ , and (1 െ ߚሻଵ/௞  for 
detecting an effect on one endpoint at the significance level of ߙ for a one-sided test, in a 
group-sequential setting with ܮ analyes. As an initial value for the sample size calculation, 
݊୫ୟ୶ is selected for Method 1, and ݊୫୧୬ and ݊୫ୟ୶ for Method 2 as Method 2 requires the two 




 The table displays the CPU time for Methods 1 and 2. The CPU time increases as the 
number of analyses increases or as the effect size decreases. Method 1 requires more 
computing time than Method 2. When calculating sample sizes for a larger number of 
analyses or when sizing to detect smaller effect sizes, an iterative procedure is required to 
save the computing time. However, if the number of analysis is larger than 5 and the number 
of endpoints is larger than 2, even iterative procedures require considerable computing time to 
compute the sample size. In these situations, a Monte-Carlo simulation-based method 
provides an alternative although the number of replications for simulations should be 
carefully chosen to control simulation error in calculating the empirical power. 
Appendix 2: Type I error rate in decision-making frameworks of hierarchical 
hypothesis testing with adaptive Type I error allocation 
We discuss the behavior of the Type I error rate in the decision-making framework for 
clinical trials with co-primary endpoints using hierarchical hypothesis testing with adaptive 
Type I error allocation (DF-B), discussed in Section 2.3. For illustration, we consider the 
simplest situation, i.e., a clinical trial with two co-primary endpoints and two analyses are 
planned. The probability for rejecting the null hypothesis for DF-B is given by 
Prሾܼଵଵ ൐ ܿଵଵሺ2ሻ, ܼଶଵ ൐ ܿଶଵሺ2ሻ|ߜଵ, ߜଶ, ߩሿ 
൅Prሾܼଵଵ ൐ ܿଵଵሺ2ሻ, ܼଶଵ ൑ ܿଶଵሺ2ሻ, ܼଶଶ ൐ ܿଶଶሺ2ሻ|ߜଵ, ߜଶ, ߩሿ 
൅Prሾܼଵଵ ൑ ܿଵଵሺ2ሻ, ܼଵଶ ൐ ܿଵଶሺ2ሻ, ܼଶଵ ൐ ܿଶଵሺ1ሻ|ߜଵ, ߜଶ, ߩሿ, 
where ܿ௞௟ሺܮ௞ሻ are the critical values for ݇th endpoint at the ݈th analysis with the maximum 
number of analyses ܮ௞. From the definitions, it is clear that the Type I error rate is a function 
of two nuisance parameters, i.e., correlation and effect sizes. The critical values for Endpoint 
2 in the first two terms are the same as those seen in the prefixed Type I error allocation 
although they are determined by the result of Endpoint 1. However the critical value for 
Endpoint 2 in the third term clearly depends on the result of Endpoint 1. 
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 As seen in Figures 5 and 6, the Type I error rate is inflated, i.e., higher than the targeted 
significance level when ሺߜଵ, ߜଶሻ ൌ(0.2, 0.0). Therefore, to evaluate the Type I error, we 
consider just the situation of ߜଵ ് 0 and ߜଶ ൌ 0. When ߩ ൌ 0, the Type I error rate for DF-B 
is 
ߙ஻ ൌ Prሾܼଵଵ ൐ ܿଵଵሺ2ሻ|ߜ1 ് 0ሿ 
ൈ ሺPrሾܼଶଵ ൐ ܿଶଵሺ2ሻ|ߜ2 ൌ 0ሿ ൅ Prሾܼଶଵ ൑ ܿଶଵሺ2ሻ, ܼଶଶ ൐ ܿଶଶሺ2ሻ|ߜ2 ൌ 0ሿሻ 
൅Prሾܼଵଵ ൑ ܿଵଵሺ2ሻ, ܼଵଶ ൐ ܿଵଶሺ2ሻ|ߜ1 ് 0ሿPrሾܼଶଵ ൐ ܿଶଵሺ1ሻ|ߜ2 ൌ 0ሿ 
൑ 	Prሾܼଵଵ ൐ ܿଵଵሺ2ሻ|ߜ1 ് 0ሿߙ ൅ Prሾܼଵଵ ൑ ܿଵଵሺ2ሻ, ܼଵଶ ൐ ܿଵଶሺ2ሻ|ߜ1 ് 0ሿߙ 
ൌ ሺ1 െ ߚଵሻߙ, 
where 1 െ ߚଵ is the power for detecting the effect size for Endpoint 1. So that when ߩ ൌ 0, 
the Type I error rate for DF-B is not larger than the targeted significance level. However, 
when ߩ ൐ 0, the Type I error rate for DF-B is inflated, depending on ߜଵ and ߩ. To illustrate 
how the Type I error rate for DF-B changes with ߜଵ and ߩ, Figures A1 to A3 provide the 
behaviors of the overall Type I error rate for DF-B as a function of correlation (ߩ) and effect 
size for Endpoint 1 (ߜଵ) under a given sample size per group (equally-sized groups) in group-
sequential strategies for clinical trials with two co-primary endpoints and two analyses. Also 
the four stopping-boundary combinations are considered as the critical value for Endpoint 2 
depends on the effect size for Endpoint 1; (i) the OF for both endpoints (OF-OF), (ii) the OF 
for ߜଵ and the PC for ߜଶ (OF-PC), (iii) the PC for ߜଵ and the OF for ߜଶ (PC-OF), and (iv) the 
PC for both endpoints (PC-PC). The sample sizes per group are calculated 86 for Figure A1, 
516 for Figure A2, 2068 for Figure A3 to detect the joint effect of ሺߜଵ, ߜଶሻ ൌ(0.5,0.5), 
(0.2,0.2), and (0.1, 0.1), with the power of 80% at the significance level of 2.5% for a one-
sided test in a fixed sample size design. For the assessment of the Type I error rate, the effect 
size combination ሺߜଵ, ߜଶሻ ൌ ሺߜଵ∗, 0ሻ is considered, where 0 ൑ ߜଵ∗ ൑ 1. Figures A1 to A3 show 




for Endpoint 1, especially with smaller sample sizes, and PC-PC and OF-PC stopping-
boundary combinations. The third term of the Type I error rate for DF-B, 	Prሾܼଵଵ ൑
ܿଵଵሺ2ሻ, ܼଵଶ ൐ ܿଵଶሺ2ሻ, ܼଶଵ ൐ ܿଶଵሺ1ሻ|ߜଵ, ߜଶ, ߩሿ is relevant for adaptive Type I error allocation 
as the critical value for Endpoint 2 is determined based on the result on the Endpoint 1 and 
contributes to inflation of the Type I error rate. 
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Table 1. O’Brien-Fleming-type boundary corresponding to the rejection of the null 
hypothesis for the first- and second-tested endpoints in hierarchical hypothesis testing 
with the adaptive Type I error allocation 
Interim analysis and 
Information time for 
the second-tested 
endpoint 
Interim analysis and information time  













4.8769 3.3569 2.6803 2.2898 2.0310   
1st (0.2) 4.8769 3.3569 2.6803 2.2898 2.0310  
2nd (0.4)  3.3569 2.6802 2.2898 2.0310  
3rd (0.6)   2.6686 2.2887 2.0306  
4th (0.8)    2.2504 2.0249  





Table 2. Several group-sequential strategies for clinical trials with two 






Number of  




1/2 1     
1 DF-B EP1 2 
  EP2 2 
2 DF-A’ EP1 2 
  EP2 2 
3 DF-A EP1 2 
  EP2 2 
4 DF-A EP1 2 
  EP2 1  
: Endpoint is tested at the information time 
: If superiority has been established for the Endpoint 1 (EP1), then the second 





Table 3. Several group-sequential strategies for clinical trials with two endpoints: Five planned 






Number of  





1/5 2/5 3/5 4/5 1        
1 DF-B EP1 5   
  EP2 5   
2 DF-A’ EP1 5   
  EP2 5   
3 DF-A EP1 5   
  EP2 5   
4 DF-A EP1 5   
  EP2 4    
5 DF-A EP1 5   
  EP2 3     
6 DF-A EP1 5   
  EP2 2      
: Endpoint is tested at the information time 







Figure 1. Behavior of the overall Type I error rate under a given maximum sample size per group (equally-sized 
groups) in group-sequential strategies for clinical trials with two co-primary endpoints as shown in Table 1 (ܮ ൌ2) 

























OF-OF OF-PC PC-OF PC-PC





























































































































































































































































































Figure 2. Behavior of the overall Type I error rate under a given maximum sample size per group (equally-sized 
groups) in group-sequential strategies for clinical trials with two co-primary endpoints as shown in Table 2 (ܮ ൌ5)  
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Figure 3. Behavior of the overall power under a given sample size per group (equally-sized groups) in group-
sequential strategies for clinical trials with two co-primary endpoints as shown in Table 1 (ܮ ൌ2) 
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Figure 4. Behavior of the overall power under a given sample size per group (equally-sized groups) in group-
sequential strategies for clinical trials with two co-primary endpoints as shown in Table 2 (ܮ ൌ5) 
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Figure 5. Behavior of the ASN under a given sample size per group (equally-sized groups) in group-sequential 
strategies for clinical trials with two co-primary endpoints as shown in Table 1 (ܮ ൌ2) 
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Figure 6. Behavior of the ASN under a given sample size per group (equally-sized groups) in group-sequential 
strategies for clinical trials with two co-primary endpoints as shown in Table 2 (ܮ ൌ5) 
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framework Advantages Disadvantages   
DF-A  Controls the Type I error rate adequately 
 Flexible to allow the option of selecting 
different timings for interim looks among 
the endpoints- this is useful when 
designing clinical trials with the endpoints 
requiring different information times such 
as progression-free survival and overall 
survival 
 Possible to stop measuring an endpoint for 
which superiority has been demonstrated – 
this is desirable if the endpoint is very 
invasive or expensive (e.g., data from a 
liver biopsy or gastro-fiberscope, or data 
from expensive imaging 
 Conservative as the rejection region of the 
null hypothesis is restricted with the 
number of endpoints  
 Difficult to maintain the integrity and 
validity of clinical trial if stop measuring 
an endpoint for which superiority has been 
demonstrated. 
DF-A’  Controls the Type I error rate adequately 
 Makes the decision-making simple and 
easy to use practice  
 Conservative as the rejection region of the 
null hypothesis is restricted with the 
number of endpoints  
 Cannot stop measuring an endpoint for 
which superiority has been demonstrated 
 Provides the lowest power and largest 
sample sizes among the decision-
frameworks 
DF-B  Provides a slightly higher power and then 
smaller sample sizes compared with the 
decision-making frameworks with 
prefixed Type I error allocation (DF-A or 
DF-A’) 
 Needs to prespecify the order of 
hypothesis testing for each endpoint even 
the endpoints are equally important 
 Inflates the Type I error rate, depending on 
the correlation among the endpoints, effect 







Table 5. The expected number of observations per intervention group for each endpoint based on the decision-
making framework DF-A under a given maximum sample size in clinical trials with two co-primary endpoints, 
EP1 and EP2. The maximum sample size per intervention group (equally-sized groups) is calculated to detect the 
joint effect for two endpoints ሺߜଵ, ߜଶሻ (ߪଵ ൌ ߪଶ ൌ 1ሻ with the overall power of 80% at the significance level of 
2.5% for a one-sided test, where one interim and one final analysis are to be performed, the critical values are 
determined by the O’Brian-Fleming-type boundary, the Pocock-type boundary or their combinations, using the 
Lan-DeMets alpha-spending method with equally-spaced increments of information, and ሺߜଵ, ߜଶሻ ൌ(0.2, 0.2), (0.2, 
0.3) and (0.3, 0.2) are selected. 
Effect size 
ሺߜଵ, ߜଶሻ 
Expected # of observations 
and sample sizes 
Stopping boundary combinations  
OF-OF OF-PC PC-OF PC-PC     






















    






















    


























Table A1. CPU Time (seconds) for computing the sample size and calculated sample size (݊௅∗ሻ. The sample size is 
calculated by two methods to detect a joint effect on all endpoint with the power of 80% at the significance level of 
2.5% for a one-sided test, where the O’Brian-Fleming-type boundary is selected for the two endpoints, with 
equally spaced increments of information 
# of 
endpoints 
# of  
analyses 
Method 1  Method 2   
CPU time(sec) (݊௅∗ሻ CPU time (sec) (݊௅∗ሻ      
2 02 9.1 (0,492) 1.4 (0,492)  
 03 33.6 (0,497) 5.1 (0,497)  
 04 36.8 (0,501) 7.9 (0,501)  
 05 185.8 (0,503) 27.5 (0,503)  
 08 12669.2 (0,508) 1946.5 (0,508)  
 10 147315.2 (0,510) 23007.9 (0,510)      
3 02 91.2 (0,547) 11.7 (0,547)  
 03 245.0 (0,552) 24.9 (0,552)  
 04 1853.9 (0,557) 234.4 (0,557)  
 05 16192.5 (0,560) 2017.2 (0,560)  
 08 >1000000.0 െ 937133.2 (0,565)  










Figure A1. Behavior of the overall Type I error rate for DF-B as a function of correlation (ߩሻ and effect size for 
Endpoint 1 (ߜଵ) under a given sample size per group (equally-sized groups: ݎ ൌ 1) in group-sequential strategies 
for clinical trials with two co-primary endpoints and two analyses, where ߪଵ ൌ ߪଶ ൌ 1.0. For the assessment of the 
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Figure A2. Behavior of the overall Type I error rate for DF-B as a function of correlation (ߩሻ and effect size for 
Endpoint 1 (ߜଵ) under a given sample size per group (equally-sized groups: ݎ ൌ 1) in group-sequential strategies 
for clinical trials with two co-primary endpoints and two analyses, where ߪଵ ൌ ߪଶ ൌ 1.0. For the assessment of the 
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Figure A3. Behavior of the overall Type I error rate for DF-B as a function of correlation (ߩሻ and effect size for 
Endpoint 1 (ߜଵ) under a given sample size per group (equally-sized groups: ݎ ൌ 1) in group-sequential strategies 
for clinical trials with two co-primary endpoints and two analyses, where ߪଵ ൌ ߪଶ ൌ 1.0. For the assessment of the 
Type I error rate, ߜଶ ൌ 0.0 is assumed. The sample size per group of 2,068 is calculated to detect the joint effect of ሺߜଵ, ߜଶሻ ൌ(0.1, 0.1) with the power of 80% at the significance level of 2.5% for a one-sided test in a fixed sample 
size design 
PC-PCOF-OF OF-PC PC-OF
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